Go Pro

Robert LeBoyer Analyst Performance

Analyst at Noble Financial

Robert LeBoyer is a stock analyst at Noble Financial in the medical sector, covering 9 publicly traded companies. Over the past year, Robert LeBoyer has issued 1 stock ratings, including and buy recommendations. While full access to Robert LeBoyer's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robert LeBoyer's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
18 Last 9 Years
Buy Recommendations
100.00% 18 Buy Ratings
Companies Covered
9 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%18 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Exchange Coverage

ExchangePercentageCount
NASDAQ
88.9% of companies on NASDAQ
8 companies
NYSEAMERICAN
11.1% of companies on NYSEAMERICAN
1 company

Robert LeBoyer, an analyst at Noble Financial, currently covers 9 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
9 companies
100.0%

Robert LeBoyer of Noble Financial specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - DRUGS
4 companies
44.4%
MED - BIOMED/GENE
4 companies
44.4%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
11.1%

Robert LeBoyer's Ratings History at Noble Financial

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
7/1/2026Lower Price Target$4.57$50.00Outperform
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
3/20/2025Reiterated Rating$17.19$70.00Outperform
Nutriband Inc. stock logo
NTRB
Nutriband
1/22/2025Initiated Coverage$7.25$13.00Outperform